Yr Athro Andrew Godkin

2026

• Lauder, S. N. et al. 2026. Optimising anti-PI3Kd and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple negative breast cancer improves outcome by removing treatment-related adverse events. Journal for ImmunoTherapy of Cancer 14 (2) e012157. (10.1136/jitc-2025-012157)

2025

• Talebi, F. et al., 2025. Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference. Presented at: 8th ImmunoRad Conference New York, USA 03-05 October 2024. Vol. 14.Vol. 1. Taylor and Francis Group. (10.1080/2162402x.2025.2507856)
• Oliver, J. et al. 2025. Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients. Cancer Immunology, Immunotherapy 75 (1) 3. (10.1007/s00262-025-04218-6)
• Burnell, S. E. A. et al. 2025. OSCAR is an online ML-powered tool for organoid cell counting using bright-field images. Cell Reports: Methods 5 (12) 101251. (10.1016/j.crmeth.2025.101251)

2024

• Padilha, A. et al. 2024. Regulatory T cells play a role in determining the tumourigenicity of the Intestinal Stem Cell Niche. Gastro Hep Advances 4 (2) 100559. (10.1016/j.gastha.2024.09.014)
• Hopkins, G. et al., 2024. Lower humoral and cellular immunity following asymptomatic SARS-CoV-2 infection compared to symptomatic infection in education (the ACE cohort). Journal of Clinical Immunology 44 (6) 147. (10.1007/s10875-024-01739-0)
• Hulin-Curtis, S. et al., 2024. A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. Cell Reports 43 (6) 114259. (10.1016/j.celrep.2024.114259)

2023

• Chen, Y. et al. 2023. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Cell Reports 42 (8) 112827. (10.1016/j.celrep.2023.112827)
• Ambati, S. et al. 2023. Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T. International Journal of Hematology (10.1007/s12185-022-03518-2)
• Pembroke, T. P. I. et al. 2023. Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019. World Journal of Hepatology 15 (1), pp.89-106. (10.4254/wjh.v15.i1.89)

2022

• Milutinovic, S. et al. 2022. Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells. Cancer Research Communications 2 (12), pp.1641-1656. (10.1158/2767-9764.CRC-21-0123)
• Lauder, S. N. et al. 2022. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. British Journal of Cancer 127 , pp.1595–1602. (10.1038/s41416-022-01917-0)
• Scurr, M. J. et al. 2022. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications 13 5422. (10.1038/s41467-022-32985-8)
• Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64 103937. (10.1016/j.msard.2022.103937)
• Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
• Bradley, R. E. et al., 2022. Persistent COVID-19 infection in Wiskott-Aldrich syndrome cleared following therapeutic vaccination: a case report. Journal of Clinical Immunology 42 , pp.32-35. (10.1007/s10875-021-01158-5)
• Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)

2021

• Burnell, S. E. A. et al. 2021. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances 2 (1) ltab025. (10.1093/immadv/ltab025)
• Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163 (4), pp.389-398. (10.1111/imm.13323)
• Humphreys, I. R. and Godkin, A. J. 2021. Reply to a scientific basis for anxiety about the emergence of resistant strains of Covid-19. QJM: An International Journal of Medicine 114 (7)(10.1093/qjmed/hcab056)
• Thomson, A. et al. 2021. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer 124 , pp.1552-1555. (10.1038/s41416-021-01283-3)
• Milutinovic, S. et al. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7 (3), pp.214-225. (10.1016/j.trecan.2020.10.001)
• MacLachlan, B. J. et al. 2021. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. European Journal of Immunology 51 (2), pp.331-341. (10.1002/eji.202048753)
• Lauder, S. N. et al. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology. Vol. 163, Elsevier. , pp.59-75. (10.1016/bs.mcb.2020.09.007)

2020

• Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8 (12), pp.1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
• Hughes, E. et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy 69 , pp.2063 - 2073. (10.1007/s00262-020-02603-x)
• Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8 (2) e000693. (10.1136/jitc-2020-000693)
• Greenshields-Watson, A. et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32 (2) 107885. (10.1016/j.celrep.2020.107885)
• Godkin, A. and Humphreys, I. R. 2020. Elevated interleukin‐6, interleukin‐10 and neutrophil : lymphocyte ratio as identifiers of severe coronavirus disease 2019 [Editorial]. Immunology 160 (3), pp.221-222. (10.1111/imm.13225)
• Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
• Bagaev, D. V. et al., 2020. VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium. Nucleic Acids Research 48 (D1), pp.D1057-D1062. gkz874. (10.1093/nar/gkz874)

2019

• MacLachlan, B. J. et al., 2019. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry 294 (52), pp.20246-20258. (10.1074/jbc.RA119.009437)
• Appanna, G. D. et al. 2019. Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome. QJM: An International Journal of Medicine 112 (10), pp.793-795. (10.1093/qjmed/hcz161)
• Madura, F. et al. 2019. TCR-induced alteration of primary MHC peptide anchor residue. European Journal of Immunology 49 (7), pp.1052-1066. (10.1002/eji.201948085)
• Thomson, A. et al. 2019. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology 19 98. (10.1186/s12876-019-1002-4)
• Besneux, M. et al., 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68 , pp.247-256. (10.1007/s00262-018-2266-1)

2018

• Hughes, E. et al. 2018. T‐cell modulation by cyclophosphamide for tumour therapy. Immunology 154 (1), pp.62-68. (10.1111/imm.12913)
• Holland, C. J. et al. 2018. In silico and structural analyses demonstrate that intrinsic protein motions guide T cell receptor complementarity determining region loop flexibility. Frontiers in Immunology 9 674. (10.3389/fimmu.2018.00674)

2017

• Colbeck, E. J. et al., 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5 (11), pp.1005-1015. (10.1158/2326-6066.CIR-17-0131)
• Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3 (10) e172579. (10.1001/jamaoncol.2017.2579)
• Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
• Godkin, A. and Smith, K. 2017. Chronic infections with viruses or parasites: breaking bad to make good. Immunology 150 (4), pp.389-396. (10.1111/imm.12703)
• Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35 (7), pp.154-154. (10.1200/JCO.2017.35.7_suppl.154)

2016

• Clement, M. et al. 2016. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. Plos Pathogens 12 (12) e1006050. (10.1371/journal.ppat.1006050)
• Jönsson, P. et al., 2016. Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions. Proceedings of the National Academy of Sciences of the United States of America 113 (20), pp.5682-5687. (10.1073/pnas.1513918113)
• Cole, D. and Godkin, A. 2016. The peptide ligands presented by MHC class II molecules. In: Encyclopedia of Immunobiology. Elsevier. , pp.209-214. (10.1016/B978-0-12-374279-7.06010-0)

2015

• Holland, C. J. et al., 2015. Enhanced detection of antigen-specific CD4+ T cells using altered peptide flanking residue peptide-MHC class II multimers. Journal of Immunology 195 (12), pp.5827-5836. (10.4049/jimmunol.1402787)
• Santegoets, S. J. A. M. et al., 2015. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunology, Immunotherapy 64 (10), pp.1271-1286. (10.1007/s00262-015-1729-x)
• Dolton, G. M. et al. 2015. More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology 146 (1), pp.11-22. (10.1111/imm.12499)
• Colbeck, E. et al. 2015. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget 6 (28), pp.24649-24659. (10.18632/oncotarget.5584)
• Scurr, M. J. et al. 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI: Journal of the National Cancer Institute 107 (4) djv001. (10.1093/jnci/djv001)
• Costa Bento, D. F. et al. 2015. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology 4 (3), pp.653-660. e974374. (10.4161/2162402X.2014.974374)
• Madura, F. et al., 2015. Structural basis for ineffective T-cell responses to MHC anchor residue-improved 'heteroclitic' peptides. European Journal of Immunology 45 (2), pp.584-591. (10.1002/eji.201445114)
• Tungatt, K. et al. 2015. Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs. Journal of Immunology 194 (1), pp.463-474. (10.4049/jimmunol.1401785)
• Ondondo, B. et al., 2015. A distinct chemokine axis does not account for enrichment of Foxp3+ CD4+T cells in carcinogen-induced fibrosarcomas. Immunology 145 (1), pp.94-104. (10.1111/imm.12430)
• Pembroke, T. , Gallimore, A. M. and Godkin, A. J. 2015. Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. Journal of Immunological Methods 424 , pp.131-135. (10.1016/j.jim.2015.04.011)

2014

• Dolton, G. M. et al. 2014. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clinical and Experimental Immunology 177 (1), pp.47-63. (10.1111/cei.12339)
• Ondondo, B. et al. 2014. Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cellsviablood vessels and lymphatics. International Journal of Cancer 134 (9), pp.2156-2167. (10.1002/ijc.28556)

2013

• Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
• Ondondo, B. et al., 2013. Home sweet home: The tumor microenvironment as a haven for regulatory T cells. Frontiers in Immunology 4 197. (10.3389/fimmu.2013.00197)
• Holland, C. J. , Cole, D. and Godkin, A. J. 2013. Re-directing CD4+ T cell responses with the flanking residues of MHC class II-bound peptides: The core is not enough. Frontiers in Immunology 4 172. (10.3389/fimmu.2013.00172)
• Pembroke, T. , Gallimore, A. and Godkin, A. 2013. Flow cytometry makes all the difference. Journal of Hepatology 59 (4), pp.909-910. (10.1016/j.jhep.2013.05.047)
• Pembroke, T. et al. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)
• Gallimore, A. M. and Godkin, A. J. 2013. Epithelial barriers, microbiota, and colorectal cancer. New England Journal of Medicine 368 (3), pp.282-284. (10.1056/NEJMcibr1212341)
• Cole, D. et al. 2013. T-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex Interactions. Journal of Biological Chemistry 289 (2), pp.628-638. (10.1074/jbc.M113.522110)
• Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43 (10), pp.2613-2625. (10.1002/eji.201243018)
• Pembroke, T. , Gallimore, A. and Godkin, A. 2013. Rapid innate control of antigen abrogates adaptive immunity. Immunology 138 (4), pp.293-297. (10.1111/imm.12048)
• Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1 (6) 416. (10.1158/2326-6066.CIR-13-0035)

2012

• Hindley, J. P. et al. 2012. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T cell depletion. Cancer Research 72 (21), pp.5473-5482. (10.1158/0008-5472.CAN-12-1912)
• Holland, C. J. et al. 2012. Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Scientific Reports 2 629. (10.1038/srep00629)
• Cole, D. et al. 2012. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications 3 665. (10.1038/ncomms1665)
• Betts, G. J. et al. 2012. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61 (8), pp.1163-1171. (10.1136/gutjnl-2011-300970)
• Humphreys, I. R. et al. 2012. Avidity of influenza-specific memory CD8+T-cell populations decays over time compromising antiviral immunity. European Journal of Immunology 42 (12), pp.3235-3242. (10.1002/eji.201242575)
• Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42 (9), pp.2383-2394. (10.1002/eji.201142072)
• Pembroke, T. et al. 2012. PMO-174 Intrahepatic natural killer cell phenotyping and functional analysis by fine needle aspiration in chronic HCV infection. Gut 61 (S2), pp.A144-A145. (10.1136/gutjnl-2012-302514b.174)
• Scurr, M. J. , Gallimore, A. M. and Godkin, A. J. 2012. PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression. Gut 61 (S2) A109. (10.1136/gutjnl-2012-302514b.88)
• Scurr, M. J. , Gallimore, A. M. and Godkin, A. J. 2012. T cell subsets and colorectal cancer: discerning the good from the bad. Cellular Immunology 279 (1), pp.21-24. (10.1016/j.cellimm.2012.08.004)

2011

• Clement, M. et al. 2011. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. The Journal of Immunology 187 (2), pp.654-663. (10.4049/jimmunol.1003941)
• Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66 (5), pp.368-374. (10.1136/thx.2010.150318)
• Godkin, A. J. and Gallimore, A. M. 2011. Setting the threshold for extra-thymic differentiation of Foxp3+ Tregs: TGF-β-dependent and T-cell autonomous. European Journal of Immunology 41 (5), pp.1218-1220. (10.1002/eji.201141576)
• Hindley, J. P. et al. 2011. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Research 71 (3), pp.736-746. (10.1158/0008-5472.CAN-10-1797)

2010

• Lauder, S. N. et al. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131 (S1), pp.186. (10.1111/j.1365-2567.2010.03390.x)
• Richards, H. C. et al. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131 (4), pp.583-592. (10.1111/j.1365-2567.2010.03333.x)
• Turner, J. et al., 2010. Clinical characteristics of hepatitis E in a "Non-Endemic" population. Journal of Medical Virology 82 (11), pp.1899-1902. (10.1002/jmv.21905)

2009

• Gallagher, K. M. E. et al. 2009. Type I interferon (IFNα) acts directly on human memory CD4+ T cells altering their response to antigen. The Journal of Immunology 183 (5), pp.2915-2920. (10.4049/jimmunol.0801607)
• Wise, M. P. et al. 2009. Latent viral infections in critically ill patients. Critical care (London, England) 13 (3) 410. (10.1186/cc7902)
• Baalasubramanian, S. et al. 2009. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. The Journal of Immunology 182 (9), pp.5203-5207. (10.4049/jimmunol.0804243)
• Lissina, A. et al., 2009. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. Journal of Immunological Methods 340 (1), pp.11-24. (10.1016/j.jim.2008.09.014)

2008

• Longhi, M. P. et al., 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4 (2) e1000006. (10.1371/journal.ppat.1000006)
• Godkin, A. J. et al. 2008. Expansion of hepatitis C-specific CD4+CD25+ regulatory T cells after viral clearance: a mechanism to limit collateral damage?. Journal of Allergy and Clinical Immunology 121 (5), pp.1277-1284. (10.1016/j.jaci.2008.01.070)

2007

• Owen, P. J. D. et al., 2007. Lesson of the week - An unusual cause of jaundice. BMJ 335 (7623), pp.773-774. (10.1136/hmj.39247.452141.BE)
• Boulter, J. M. et al. 2007. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology 37 (3), pp.798-806. (10.1002/eji.200636743)
• Simon, A. K. et al., 2007. Regulatory T cells inhibit Fas ligand induced innate and adaptive tumour immunity. European Journal of Immunology 37 (3), pp.758-767. (10.1002/eji.200636593)
• Betts, G. et al., 2007. The impact of regulatory T cells on carcinogen-induced sarcogenesis. British Journal of Cancer 96 (12), pp.1849-1854. (10.1038/sj.bjc.6603824)
• Betts, G. J. , Godkin, A. J. and Gallimore, A. M. 2007. Reply: forkhead box P3-positive regulatory T cells in immune surveillance and cancer. British Journal of Cancer 97 , pp.1017-1018. (10.1038/sj.bjc.6603940)
• Gallimore, A. M. and Godkin, A. J. 2007. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 123 (2), pp.157-163. (10.1111/j.1365-2567.2007.02748.x)
• Lewis, G. et al. 2007. A case of persistent anemia and alcohol abuse. Nature Clinical Practice Gastroenterology & Hepatology 4 (9), pp.521-526. (10.1038/ncpgasthep0922)
• Owen, P. J. D. et al. 2007. An unusual cause of jaundice. British Medical Journal (BMJ) 335 (7623), pp.773. (10.1136/bmj.39247.452141.BE)

2006

• Godkin, A. J. et al. 2006. CD4CD25FOXP3 Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer. PLoS ONE 1 (1) e129. (10.1371/journal.pone.0000129)
• Betts, G. J. et al. 2006. Regulating the immune response to tumours. Advanced Drug Delivery Reviews 58 (8), pp.948-961. (10.1016/j.addr.2006.05.006)
• Wise, M. P. , Gallimore, A. M. and Godkin, A. J. 2006. T-Cell costimulation [Letter]. New England Journal of Medicine 355 (24), pp.2594-2595. (10.1056/NEJMc062767)

2005

• Godkin, A. J. , Hill, A. V. and Davenport, M. 2005. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology 41 (6), pp.1383-1390. (10.1002/hep.20716)
• Clarke, S. L. et al., 2005. Analysis of CD4(+)CD25(hi) cells in peripheral blood and lymph nodes of patients with colorectal cancer. Immunology 116 (1), pp.37-37. (10.1111/j.1365-2567.2005.02287.x)
• Godkin, A. J. , Openshaw, P. and Thomas, H. C. 2005. Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant. Journal of Viral Hepatitis 12 (6), pp.604-608. (10.1111/j.1365-2893.2005.00627.x)

2003

• Harcourt, G. C. et al., 2003. Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection. Clinical and Experimental Immunology 131 (1), pp.122-129. (10.1046/j.1365-2249.2003.02033.x)

2002

• Godkin, A. J. , Thomas, H. C. and Openshaw, P. J. 2002. Evolution of epitope-specific memory CD4+ T cells after clearance of Hepatitis C virus. The Journal of Immunology 169 (4), pp.2210-2214. (10.4049/jimmunol.169.4.2210)
• Godkin, A. J. et al. 2002. A population of CD25+CD4+regulatory cells that recognise hepatitis C virus antigens can be identified following clearance of infection. Gastroenterology 122 (4), pp.A676-A676.
• Godkin, A. J. , Openshaw, P. and Thomas, H. 2002. Characterisation of epitope-specific functionally distinct CD4+memory cell populations after clearance of hepatitis C virus (HCV). Gastroenterology 122 (4), pp.A640-A640.
• Popat, S. et al., 2002. Genome screening of coeliac disease [Letter]. Journal of Medical Genetics 39 (5), pp.328-331. (10.1136/jmg.39.5.328)

2001

• Godkin, A. J. et al. 2001. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. Journal of Immunology 166 (11), pp.6720-6727.
• Godkin, A. J. et al. 2001. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. European Journal of Immunology 31 (5), pp.1438-1446.

2000

• Godkin, A. J. , Thompson, M. and Summerfield, J. 2000. Abdominal pain and melaena: an unusual cause. The Lancet 356 (9229), pp.562-563. (10.1016/S0140-6736(00)02582-4)
• Anderson, R. P. et al., 2000. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nature Medicine 6 (3), pp.337-342. (10.1038/73200)
• Godkin, A. J. et al. 2000. Identification of HLA-DR11-restricted CD4+T cell epitopes derived from hepatitis C virus. Hepatology 32 (4), pp.271A-271A.

1999

• Bevan, S. et al., 1999. Contribution of the MHC region to the familial risk of coeliac disease. Journal of Medical Genetics 36 (9), pp.687-690. (10.1136/jmg.36.9.687)

1998

• Godkin, A. J. et al. 1998. Use of complete eluted peptide sequence data from HLA-DR and -DQ molecules to predict T cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection. The Journal of Immunology 161 (2), pp.850-858.
• Gallimore, A. et al., 1998. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. Journal of Experimental Medicine 187 (9), pp.1383-1393.
• Godkin, A. J. and Jewell, D. 1998. The pathogenesis of celiac disease. Gastroenterology 115 (1), pp.206-210. (10.1016/S0016-5085(98)70382-8)

1997

• Davenport, M. P. et al., 1997. A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. Immunogenetics 45 (3), pp.229-232. (10.1007/s002510050196)
• Godkin, A. J. et al. 1997. Binding characteristics of synthetic ligands from A-gliadin to the coeliac disease susceptibility molecules HLA-DQ2/8, and the linked molecules HLA-DR3/4. Gastroenterology 112 (4), pp.A364-A364.
• Godkin, A. J. et al. 1997. Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). International Immunology 9 (6), pp.905-911. (10.1093/intimm/9.6.905)
• Godkin, A. J. et al. 1997. Possible immuno-modulatory activity of gliadin by interference with antigen processing. Gastroenterology 112 (4), pp.A365-A365.
• Houlston, R. S. et al., 1997. Linkage analysis of candidate regions for coeliac disease genes. Human Molecular Genetics 6 (8), pp.1335-1339. (10.1093/hmg/6.8.1335)

1996

• Godkin, A. J. et al. 1996. Pool sequencing of naturally bound peptides from the HLA class II DQ2 allele and use of this data for T-cell epitope prediction in coeliac disease. Gastroenterology 110 (4), pp.A326-A326.
• Godkin, A. J. et al. 1996. Expression of nitric oxide synthase in ulcerative colitis. European Journal of Clinical Investigation 26 (10), pp.867-872. (10.1111/j.1365-2362.1996.tb02131.x)

1994

• Godkin, A. J. , Dinning, W. J. and Anderson, M. G. 1994. Scleritis associated with Coxsackle B type 5 infection [Letter]. Eye 8 (3), pp.357-358. (10.1038/eye.1994.76)

• Godkin, A. J. , Brookes, R. and Jewell, D. P. null. Identification of a coeliac disease-specific T cell eptope from A-gliadin. Gastroenterology 116 (4), pp.A882-A882.